US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles (Q36058902)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q64857220)
(P304) 239-252
(P407) (Q1860)
(P433) 3
(P478) 19
(P577) Saturday, January 1, 2005
(P921) (Q8277)
(P1433) (Q5013183)
(P1476) "US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles" (language: en)
(P2093) Clyde Markowitz
(P2860) (Q44264108)
(Q34308006)
(Q34924287)
(Q34375520)
(Q77573170)
(Q28137954)
(Q44412470)
(Q39455318)
(Q73933826)
(Q73086132)
(Q34511062)
(Q44151598)
(Q78571161)
(Q46205108)
(Q41622099)
(Q70650973)
(Q50676603)
(Q40873994)
(Q78571167)
(Q48489376)
(Q74009722)
(Q44543138)
(Q47951812)
(Q36657495)
(Q77573167)
(Q44351935)
(Q74405429)
(Q43800485)
(Q34371405)
(Q42068700)
(Q74249240)
(Q34975819)
(Q59649521)
(Q73727558)
(Q40643606)
(Q28293763)
(Q40583199)
(Q33836477)
(Q30689329)
(Q71899123)
(Q44344138)
(Q77845065)
(Q35153077)
(Q53989176)
(Q44443464)
(Q47272342)
(Q35674444)
(P13046) (Q7318358)
other details
description scientific article

External Links